title: T-cell immunity generated by recombinant adenovirus vaccines.
abstract: Recombinant adenovirus vaccines show great promise for generating protective immunity against infectious agents and tumors. Our studies have identified several interesting biological features of the adenovirus vector that influence the T-cell response. Notably, we have demonstrated that following immunization with adenovirus vaccines, the transgene antigen remains available to the system for a longer period than would be expected, resulting in a T-cell population with a sustained effector phenotype. The implications of these observations with regards to the utility of adenovirus vaccines are discussed.
authors.affiliation: Center for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada. yangtt@mcmaster.ca
authors.forename: Teng Chih
authors.initials: TC
authors.lastname: Yang
authors.forename: James B
authors.initials: JB
authors.lastname: Millar
authors.forename: Natalie
authors.initials: N
authors.lastname: Grinshtein
authors.forename: Jennifer
authors.initials: J
authors.lastname: Bassett
authors.forename: Jonathan
authors.initials: J
authors.lastname: Finn
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Bramson
mesh_terms: D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology*; D000818:Animals; D017951:Antigen Presentation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology; D005822:Genetic Vectors; D006801:Humans; D014614:Vaccines, Synthetic / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; D014765:Viral Vaccines